公开(公告)号：US20200054640A1

公开(公告)日：2020-02-20

申请号：US16544180

申请日：2019-08-19

Applicant: Memorial Sloan-Kettering Cancer Center ,  St. Jude Children's Research Hospital

Inventor： Scott William LOWE ,  Charles J. SHERR ,  Chun-Hao HUANG ,  Amaia LUJAMBIO

IPC: A61K31/519 ,  C12Q1/6886 ,  A61K31/7048 ,  A61K31/655 ,  A61K31/4745 ,  A61K31/4545 ,  C12N15/113 ,  G01N33/574 ,  A61K45/06 ,  A61K31/7068 ,  A61K31/445 ,  A61K31/44 ,  A61K31/404 ,  A61K31/40

Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.

公开(公告)号：US10538739B2

公开(公告)日：2020-01-21

申请号：US15337854

申请日：2016-10-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: A61K35/17 ,  C12N5/0783 ,  A61K38/00 ,  C07K14/725 ,  C07K14/705 ,  C12N5/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US10526380B2

公开(公告)日：2020-01-07

申请号：US15794503

申请日：2017-10-26

Applicant: St. Jude Children's Research Hospital

Inventor： Joseph Paul Taylor ,  Peipei Zhang

IPC: C12N15/82 ,  C07K14/415 ,  C12N9/14 ,  C12N13/00

Abstract: A nucleic acid molecule encoding a fusion protein composed of a plant cryptochrome at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for light-dependent, G3BP-mediated stress granule formation.

公开(公告)号：US10441601B2

公开(公告)日：2019-10-15

申请号：US15740687

申请日：2016-06-30

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stanislav S. Zakharenko

IPC: C12N15/11 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/6883 ,  A61K9/00 ,  C12N15/861 ,  C12Q1/6841

Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.

公开(公告)号：US10266544B2

公开(公告)日：2019-04-23

申请号：US15024549

申请日：2014-09-29

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Richard E. Lee ,  Samanthi L. Waidyarachchi ,  David F. Bruhn ,  Jiuyu Liu ,  Zhong Zheng ,  Jason W. Rosch

IPC: C07D493/04 ,  A61K9/00 ,  A61K31/357 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4045 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06

Abstract: The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.

公开(公告)号：US20190099451A1

公开(公告)日：2019-04-04

申请号：US16082359

申请日：2017-03-08

Applicant: St. Jude Children's Research Hospital

Inventor： Sheng Zhou ,  Brian Sorrentino ,  Melissa Bonner

IPC: A61K35/30 ,  A61K38/17 ,  C12N15/85 ,  C12N15/62 ,  A61K35/28 ,  C12N5/0789

Abstract: A retroviral construct harboring nucleic acids encoding a high mobility group AT-hook 2 (HMGA2) protein and lacking let-7 binding sites is described as are methods of using the retroviral vector to increase the efficacy and in vivo expansion of transduced cells in gene therapy applications.

公开(公告)号：US20190048040A1

公开(公告)日：2019-02-14

申请号：US16160724

申请日：2018-10-15

Applicant: St. Jude Children's Research Hospital

Inventor： Richard E. Lee ,  Ying Zhao ,  Liu Jiuyu

IPC: C07K11/02 ,  C07D498/14 ,  A61K38/15 ,  A61K9/20 ,  A61K47/02 ,  A61K9/00 ,  C07D498/22 ,  A61K45/06 ,  C07K7/06 ,  A61K38/12 ,  A61K38/14 ,  A61K31/407

Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20190040381A1

公开(公告)日：2019-02-07

申请号：US15780938

申请日：2016-12-02

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Paul Thomas ,  Xizhi Guo ,  Pradyot Dash

IPC: C12N15/10 ,  C12N15/66

Abstract: The invention provides a method for rapid cloning of T-cell receptors (TCRs) (e.g., paired αβ and γδ TCR chains) and B-cell receptors (BCRs) (e.g. paired IgH or IgK or Igλ) from single cells by CDR3 substitution using single cell PCR products and Gibson Assembly techniques and a pre-generated TCR (or BCR) library in an expression vector.

公开(公告)号：US20180369363A1

公开(公告)日：2018-12-27

申请号：US16126791

申请日：2018-09-10

Applicant: Icahn School of Medicine at Mount Sinai ,  St. Jude Children's Research Hospital ,  The United States of America, As Represented by the Secretary of Agriculture

Inventor： Peter Palese ,  Adolfo Garcia-Sastre ,  Richard J. Webby ,  Juergen A. Richt ,  Robert G. Webster ,  Kelly M. Lager

IPC: A61K39/145 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

公开(公告)号：US20180318331A1

公开(公告)日：2018-11-08

申请号：US15740687

申请日：2016-06-30

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stanislav S. ZAKHARENKO

IPC: A61K31/713 ,  C12N15/113 ,  A61K9/00

CPC classification number: A61K31/713 ,  A61K9/0043 ,  C12N15/113 ,  C12N15/861 ,  C12N2310/141 ,  C12Q1/6841 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/178 ,  G01N2800/302

Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.